Theory Paper IIDrNB Cardiology – Theory Notes

ANTICOAGULATION IN PREGNANCY

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITION AND PHYSIOLOGICAL RATIONALE (ESC PREGNANCY GUIDELINES)

  • Physiological Hypercoagulability of Pregnancy: Normal pregnancy induces a prothrombotic physiological state characterized by marked increases in coagulation factors VII, VIII, X, von Willebrand factor, and fibrinogen, decreased free Protein S activity, acquired resistance to activated Protein C, and venous stasis from gravid uterine compression of the inferior vena cava.
  • The Clinical Balancing Act: Anticoagulation in pregnancy (indicated primarily for Mechanical Prosthetic Heart Valves, Venous Thromboembolism [VTE], or high-risk Atrial Fibrillation / Intracardiac Shunts) must balance the prevention of fatal maternal valve thrombosis or pulmonary embolism against the risks of fetal teratogenicity (Warfarin embryopathy), fetal intracranial hemorrhage, and maternal peripartum hemorrhage.

IIPLACENTAL TRANSFER AND SAFETY PROFILES OF ANTICOAGULANTS

  • Low Molecular Weight Heparin (LMWH — Enoxaparin, Dalteparin):
    • Placental Transfer: Does NOT cross the placental barrier; completely free of fetal teratogenicity or fetal bleeding risk.
    • Altered Pregnancy Pharmacokinetics: Maternal plasma volume expansion (by 40 to 50 percent) and a 50 percent increase in Glomerular Filtration Rate (GFR) accelerate renal clearance of LMWH, rendering fixed weight-based dosing inadequate for mechanical valves.
    • Mandatory Anti-Xa Monitoring (Class I): For mechanical prosthetic valves, LMWH must be administered twice daily with weekly or bi-weekly Peak Anti-Xa monitoring drawn 4 hours post-injection (targeting 0.8 to 1.2 U/mL for aortic valves and 1.0 to 1.2 U/mL for mitral/right-sided valves), plus trough Anti-Xa levels prior to the next dose maintained at 0.6 U/mL or greater.
    • Unfractionated Heparin (UFH):
    • Placental Transfer: Does NOT cross the placenta.
    • Clinical Role: Used primarily during the peripartum window (from 36 weeks of gestation to delivery) as a continuous intravenous infusion (target aPTT >=2.0 times control) because of its short half-life (1 to 2 hours) and complete, rapid reversibility with Protamine Sulfate. Prolonged use throughout pregnancy is avoided due to maternal osteoporosis, heparin-induced thrombocytopenia (HIT), and erratic subcutaneous absorption.
    • Vitamin K Antagonists (VKAs — Warfarin, Acenocoumarol):
    • Placental Transfer: Freely CROSSES the placenta.
    • First-Trimester Teratogenicity (Weeks 6 to 12): Disrupts vitamin K-dependent osteocalcin/matrix Gla protein synthesis during fetal organogenesis, causing Warfarin Embryopathy (nasal bone hypoplasia, depressed nasal bridge, and stippled epiphyses [chondrodysplasia punctata]).
    • Second/Third-Trimester and Delivery Risks: Causes a low (1 to 2 percent) risk of fetal CNS/ocular anomalies and a high risk of fatal fetal intracranial hemorrhage during traumatic vaginal delivery if Warfarin is not discontinued at week 36 (as the immature fetal liver has low clotting factor levels and clears Warfarin slowly).
    • Crucial Dose-Dependency Threshold: The risk of Warfarin embryopathy and fetal loss is strictly dose-dependent: when the maternal Warfarin dose is 5 mg/day or less (or Acenocoumarol <=2 mg/day), the risk of embryopathy is low (less than 1 to 3 percent), whereas at doses greater than 5 mg/day, embryopathy and fetal loss rates rise sharply (exceeding 8 to 10 percent).
    • Direct Oral Anticoagulants (DOACs — Apixaban, Rivaroxaban, Dabigatran, Edoxaban) and Fondaparinux:
    • DOACs (Class III — Strictly Contraindicated): DOACs cross the placenta, are associated with reproductive toxicity/miscarriage, and are strictly contraindicated in both pregnancy and mechanical prosthetic valves (per the RE-ALIGN and PROACT Xa trials). (Fondaparinux crosses the placenta in small amounts and is reserved only for severe HIT when danaparoid is unavailable.)
Anticoagulant Class Crosses Placenta? Maternal Valve Protection Fetal Risk Profile Mandatory Monitoring & Target
Warfarin (VKA) <=5 mg/day Yes Highest (~1–3% valve thrombosis) Low embryopathy (<1–3% in Wk 6–12); high fetal ICH risk if used in vaginal delivery Weekly/bi-weekly INR (Mitral: 2.5–3.5; Aortic: 2.0–3.0)
Warfarin (VKA) >5 mg/day Yes Highest High embryopathy (>8–10%) & fetal loss in Weeks 6–12 Switch to LMWH/UFH during Weeks 6–12, then resume VKA in Weeks 13–35
LMWH (Twice Daily) No (Fetal safe) Intermediate (~5–9% valve thrombosis; fatal if unmonitored) Zero teratogenicity or fetal bleeding Weekly/bi-weekly 4-h Peak Anti-Xa (0.8–1.2 U/mL AVR; 1.0–1.2 U/mL MVR) + Trough >=0.6 U/mL
Intravenous UFH No (Fetal safe) Intermediate; ideal for Week 36 to Delivery Zero fetal risk; maternal HIT & osteoporosis if prolonged aPTT >= 2.0x control (checked every 6–12 h during IV infusion)
DOACs Yes Ineffective / Harmful in mechanical valves Embryotoxic / Contraindicated Class III (Harm): Strictly Contraindicated

IIITRIMESTER-BY-TRIMESTER PROTOCOL FOR MECHANICAL PROSTHETIC VALVES (ESC / ACC-AHA)

  • Strategy A — Low Baseline Warfarin Dose Requirement (Warfarin <=5 mg/day):
    • First Trimester (Weeks 6 to 12): Continue Warfarin throughout the first trimester (Class IIa preferred option), as it provides the lowest maternal valve thrombosis and mortality rate with a very low (<3%) embryopathy risk.
    • Second and Third Trimesters (Weeks 13 to 35): Continue Warfarin (Class I).
    • Peripartum Window (Week 36 to Delivery): Discontinue Warfarin at Week 36 and hospitalize to switch to continuous IV UFH (aPTT >=2.0x) or therapeutic dose-adjusted LMWH (Anti-Xa 0.8 to 1.2 U/mL).
    • Strategy B — High Baseline Warfarin Dose Requirement (Warfarin >5 mg/day):
    • First Trimester (Weeks 6 to 12): Discontinue Warfarin between Weeks 6 and 12 and switch to in-hospital dose-adjusted twice-daily LMWH (with strict weekly Peak and Trough Anti-Xa monitoring) or continuous IV UFH (Class IIa) to avoid high-dose Warfarin embryopathy.
    • Second and Third Trimesters (Weeks 13 to 35): Switch BACK to Warfarin at Week 13 (once fetal organogenesis is complete) and continue until Week 35 (Class I).
    • Peripartum Window (Week 36 to Delivery): Discontinue Warfarin at Week 36 and transition to IV UFH or monitored LMWH.

IVDELIVERY, EMERGENCY CESAREAN AND POSTPARTUM PROTOCOL

  • Planned Delivery Timing: Planned vaginal delivery (with assisted second stage) is preferred in stable patients to minimize maternal blood loss and thrombosis risk:
  • Switch from LMWH to continuous IV UFH at least 36 hours prior to planned delivery (or hold the last therapeutic LMWH dose at least 24 hours before neuraxial epidural anesthesia or induction).
  • Stop IV UFH infusion 4 to 6 hours prior to delivery and confirm normal aPTT.
  • Restart IV UFH 4 to 6 hours postpartum (provided there is no active obstetric bleeding or spinal hematoma) and re-initiate oral Warfarin 24 to 48 hours postpartum, overlapping heparin until the INR is therapeutic for 2 consecutive days (Warfarin is completely safe during breastfeeding, as it is not excreted in active form into breast milk).
  • Emergency Delivery While Fully Anticoagulated on Warfarin (Class I): If a woman goes into preterm labor while still taking Warfarin, Vaginal Delivery is Contraindicated due to the high risk of fatal fetal cranial compression hemorrhage; an urgent Cesarean Section must be performed after reversing maternal/fetal anticoagulation with Fresh Frozen Plasma (FFP) or 4-factor Prothrombin Complex Concentrate (PCC) + low-dose IV Vitamin K (plus Fresh Frozen Plasma + Vitamin K administered directly to the neonate at birth).

VLANDMARK REGISTRY EVIDENCE (ROPAC REGISTRY)

  • ROPAC Registry (van Hagen et al., Circulation 2015): In the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC) evaluating 212 pregnant women with mechanical heart valves, maternal mortality was 1.4 percent, mechanical valve thrombosis occurred in 4.7 percent (half of which occurred during the first-trimester switch to heparin), hemorrhagic complications occurred in 23.1 percent, and only 58 percent of women had an uncomplicated pregnancy resulting in a live birth—confirming that VKA throughout pregnancy yields the lowest maternal thrombosis rate, while unmonitored or sub-therapeutic LMWH carries catastrophic maternal risk.

Key references

  • Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy, European Heart Journal, 2018.
  • Otto CM, Nishimura RA, Bonow RO, et al.: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, Circulation, 2021.
  • van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. (ROPAC Investigators): Pregnancy in Women With a Mechanical Heart Valve: Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC), Circulation, 2015.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.